

Honorable Robert S. Lasnik

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

UNITED STATES DISTRICT COURT  
WESTERN DISTRICT OF WASHINGTON  
AT SEATTLE

KING COUNTY and CITY OF  
TACOMA, individually and on behalf of  
others similarly situated,

Plaintiffs,

v.

TEVA PHARMACEUTICAL  
INDUSTRIES, LTD., TEVA  
PHARMACEUTICALS USA, INC., and  
TEVA NEUROSCIENCE, INC.,

Defendants.

No. 2:21-cv-00477-RSL

**STIPULATED MOTION AND  
ORDER REGARDING BRIEFING  
SCHEDULE FOR MOTION TO  
DISMISS FIRST AMENDED  
COMPLAINT**

**INTRODUCTION**

Defendants Teva Pharmaceuticals USA, Inc. (“Teva Pharmaceuticals”), Teva  
Neuroscience, Inc. (“Teva Neuroscience”), and Teva Pharmaceutical Industries, Ltd., (“TPI”)  
(Teva Pharmaceuticals, Teva Neuroscience, and TPI collectively, “Defendants”) and Plaintiffs  
King County and City of Tacoma (collectively, “Plaintiffs”) seek this Court’s approval of a  
briefing schedule and enlarged page limitation for briefing on Defendants’ anticipated Motion to  
Dismiss Plaintiffs’ First Amended Complaint as set forth below.

1 **BACKGROUND**

2 Plaintiffs filed their putative class action Complaint against Defendants on April 8, 2021.  
3 *See* Complaint (Dkt. No. 1). Teva Pharmaceuticals and Teva Neuroscience were served with a  
4 summons and the Complaint shortly thereafter. *See* Dkt. Nos. 5-6. Following the Court’s  
5 approval of a Stipulated Motion to Extend the Deadline for Teva Pharmaceuticals and Teva  
6 Neuroscience to respond to the Complaint, Teva Pharmaceuticals and Teva Neuroscience moved  
7 for leave to file an over-length Motion to Dismiss, which the Court granted on June 22, 2021.  
8 *See* Order Granting Defendants’ Motion for Over-Length Brief (Dkt. No. 22).

9 Teva Pharmaceuticals and Teva Neuroscience filed their Motion to Dismiss on July 2,  
10 2021. *See* Joint Motion to Dismiss (Dkt. No. 27). Shortly thereafter, Plaintiffs and Defendants  
11 stipulated to a briefing schedule on the Joint Motion to Dismiss, which the Court approved on  
12 July 7, 2021. *See* Order Regarding Briefing Schedule on Motion to Dismiss (Dkt. No. 29).

13 On or about July 6, 2021, a summons and the Complaint were served upon TPI in Tel  
14 Aviv, Israel. TPI believes that this Court lacks personal jurisdiction over it. Further, TPI wished  
15 to adopt the arguments made by Teva Pharmaceuticals and Teva Neuroscience in the Joint  
16 Motion to Dismiss. Given the pendency of the Joint Motion to Dismiss, the Parties proposed a  
17 briefing schedule for TPI’s Motion to Dismiss. Under that briefing schedule, Plaintiffs would  
18 file an omnibus response to the Joint Motion to Dismiss and TPI’s Motion to Dismiss and  
19 Defendants would file an omnibus reply in support of those motions. Further, the combined  
20 length of the Joint Motion to Dismiss and TPI’s Motion to Dismiss and the length of Plaintiffs’  
21 omnibus response to those motions could be up to sixty (60) pages. This Court approved the  
22 Parties’ Stipulated Motion Regarding Briefing on the Motions to Dismiss on July 22, 2021. *See*  
23 Order Regarding Briefing Schedule on Motions to Dismiss (Dkt. No. 38). TPI filed its Motion to  
24 Dismiss on August 30, 2021. *See* Dkt. No. 39.

25 After TPI’s filing of its Motion to Dismiss, Plaintiffs elected to amend their Complaint  
26 under Fed. R. Civ. P. 15(a)(1)(B) and Fed. R. Civ. P. 15(a)(2). The Parties conferred and agreed

1 that the deadline for Plaintiffs to amend their Complaint should be extended to September 28,  
2 2021, and that upon filing of an amended Complaint the pending Motions to Dismiss should be  
3 denied as moot. The Parties stipulated to that effect, and the Court approved the Parties'  
4 stipulation on September 20, 2021. *See* Order Extending Deadline to Amend Complaint (Dkt.  
5 No. 43). Plaintiffs filed their First Amended Complaint (the "FAC") (Dkt. No. 45) on September  
6 28, 2021.

7 For the reasons set forth in Teva Pharmaceuticals and Teva Neuroscience's Motion for  
8 Over-length Brief (Dkt. No. 20) and because TPI intends additionally to move to dismiss for lack  
9 of personal jurisdiction, the Parties have conferred and agree that, subject to this Court's  
10 approval, additional pages should be granted and the briefing schedule should be enlarged for  
11 Defendants' anticipated Motion to Dismiss the FAC. The Parties propose that:

12 1. Defendants' Motion to Dismiss be filed no later than November 17, 2021,  
13 and that the page limitation be fifty-five (55);

14 2. Plaintiffs' Opposition to Defendants' anticipated Motion to Dismiss be  
15 filed no later than January 17, 2022, and that the page limitation be fifty-five (55); and

16 3. Defendants' Reply in Support of the Motion to Dismiss be filed no later  
17 than February 16, 2022, and that the page limitation be twenty-seven (27).

18 Additionally, as the Parties agreed in their Joint Status Report and Discovery Plan (Dkt.  
19 No. 19), the Parties believe that the deadline for Plaintiffs' anticipated Motion for Class  
20 Certification should not be set until after the Court resolves Defendants' anticipated Motion to  
21 Dismiss. The Parties believe good cause exists to extend the deadline for class certification  
22 under LCR 23(i)(3) due to the anticipated pendency of Defendants' Motion to Dismiss, the  
23 complexity of the transactions involved, and the size of the proposed class.

24 Accordingly, the Parties agree, subject to this Court's approval, to the following:  
25  
26

1 **STIPULATION**

2 1. Defendants’ Motion to Dismiss, not to exceed fifty-five (55) pages, shall be filed  
3 no later than November 17, 2021;

4 2. Plaintiffs’ Opposition to Defendants’ Motion to Dismiss, not to exceed fifty-five  
5 (55) pages shall be filed no later than January 17, 2022;

6 3. Defendants’ Reply in Support of the Motion to Dismiss, not to exceed twenty-  
7 seven (27) pages, shall be filed no later than February 16, 2022;

8 4. Defendants’ Motion to Dismiss shall be noted for Friday, February 18, 2022; and

9 5. Good cause—specifically the anticipated pendency of Defendants’ Motion to  
10 Dismiss, the complexity of the transactions involved, and the size of the proposed class—exists  
11 to extend the deadline for Plaintiffs’ Motion for Class Certification beyond the default deadline  
12 set forth in LCR 23(i)(3). Unless the Defendants’ anticipated Motion to Dismiss results in  
13 dismissal of this case, the Parties are directed to meet and confer following the Court’s resolution  
14 of that motion and submit a status report including a proposed case schedule (or schedules if  
15 agreement cannot be reached), including a deadline for the Class Certification Motion, within 30  
16 days of this Court’s resolution of Defendants’ Motion to Dismiss.

17  
18 DATED: October 4, 2021.

19 **KELLER ROHRBACK L.L.P.**

**KIRKLAND & ELLIS LLP**

20 By: /s/ Alison E. Chase  
21 Lynn Lincoln Sarko, WSBA #16569  
22 Gretchen Freeman Cappio, WSBA #29576  
23 Matthew M. Gerend, WSBA #43276  
24 Felicia J. Craick, WSBA #54505  
25 1201 Third Avenue, Suite 3200  
26 Seattle, WA 98101  
lsarko@kellerrohrback.com  
gcappio@kellerrohrback.com  
mgerend@kellerrohrback.com  
fcraick@kellerrohrback.com

By: /s/ Matt Owen  
Devora W. Allon (admitted *pro hac vice*)  
Jay Lefkowitz (admitted *pro hac vice*)  
601 Lexington Avenue  
New York, NY 10022  
Phone: (212) 446-5967  
Fax: (212) 446-4900  
devora.allon@kirkland.com  
lefkowitz@kirkland.com

Matt Owen (admitted *pro hac vice*)  
1301 Pennsylvania Avenue, N.W.

1 Alison E. Chase (admitted *pro hac vice*)  
2 801 Garden Street, Suite 301  
3 Santa Barbara, CA 93101  
achase@kellerrohrback.com

4 *Attorneys for Plaintiffs King County*  
5 *and City of Tacoma*

Washington, D.C. 20004  
Tel: (202) 389-5100  
Fax: (202) 389-5000  
john.bailey@kirkland.com  
matt.owen@kirkland.com

**ARETE LAW GROUP PLLC**

By: /s/ Jeremy E. Roller  
Jeremy E. Roller, WSBA No. 32021  
1218 Third Avenue, Suite 2100  
Seattle, WA 98101  
Phone: (206) 428-3250  
Fax: (206) 428-3251  
jroller@aretelaw.com

*Attorneys for Defendants Teva Pharmaceuticals  
USA, Inc., Teva Neuroscience, Inc., and Teva  
Pharmaceutical Industries, Ltd.*

**ORDER**

15 IT IS SO ORDERED.

17 DATED: October 5, 2021.

18 

19 Robert S. Lasnik  
20 United States District Judge